Dean Phizacklea - CochLear Senior Vice President Global Marketing
| CHEOY Stock | USD 97.60 1.46 1.52% |
President
Mr. Dean Phizacklea serves as Senior Vice President Global Marketing of the Company. He joined Cochlear in June 2016. Dean has responsibility for product marketing and commercialisation, consumer marketing, innovation, market access, market insights and corporate communications. Dean has more than 20 years experience in medical devices and pharmaceuticals, covering a range of senior commercial roles in the US, Japan, Europe and Australia. Prior to joining Cochlear, Dean led Global Strategic Marketing for Abbott Diabetes Care. Other roles include General Manager for Abbott pharmaceutical and diabetes care businesses in AustraliaNew Zealand and commercial roles in Asia with AstraZeneca. since 2016.
| Tenure | 8 years |
| Phone | 61 2 9428 6555 |
| Web | https://www.cochlear.com |
CochLear Management Efficiency
The company has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1713 %, meaning that it generated $0.1713 on every $100 dollars invested by stockholders. CochLear's management efficiency ratios could be used to measure how well CochLear manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jared Watkin | Abbott Laboratories | 56 | |
| Payman Khales | Integer Holdings Corp | 54 | |
| Vasant Padmanabhan | Smith Nephew SNATS | 57 | |
| Huimin Wang | Edwards Lifesciences Corp | 64 | |
| Brent Ladd | Stryker | N/A | |
| Andrew Lane | Abbott Laboratories | 49 | |
| Scott Ullem | Edwards Lifesciences Corp | 57 | |
| Glenn Boehnlein | Stryker | 62 | |
| John Capek | Abbott Laboratories | 59 | |
| Catherine Szyman | Edwards Lifesciences Corp | 54 | |
| Eric Thepaut | Boston Scientific Corp | 59 | |
| Yin Becker | Stryker | 57 | |
| Joseph Flanagan | Integer Holdings Corp | 61 | |
| Bernard Zovighian | Edwards Lifesciences Corp | 56 | |
| Jodi Eddy | Boston Scientific Corp | 50 | |
| Larry Wood | Edwards Lifesciences Corp | 58 | |
| JeanLuc Lemercier | Edwards Lifesciences Corp | 67 | |
| Donald Bobo | Edwards Lifesciences Corp | 62 | |
| Paul Connolly | Smith Nephew SNATS | 56 | |
| Brian White | Stryker | N/A | |
| Mark Gladwell | Smith Nephew SNATS | 44 | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 |
CochLear ADR Leadership Team
Elected by the shareholders, the CochLear's board of directors comprises two types of representatives: CochLear inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CochLear. The board's role is to monitor CochLear's management team and ensure that shareholders' interests are well served. CochLear's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CochLear's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stuart Sayers, President - Services | ||
| David Hackshall, Chief Officer | ||
| MBA BE, MD, CEO | ||
| Anthony Bishop, President - Asia Pacific | ||
| Dean Phizacklea, Senior Vice President Global Marketing | ||
| Richard MBA, Pres EMEA | ||
| Jennifer Stevenson, VP Brand | ||
| Jan Eng, Chief Officer | ||
| Kristina Devon, VP Relations | ||
| Lisa Aubert, Pres America |
CochLear Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CochLear a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 9.05 B | |||
| Shares Outstanding | 131.56 M | |||
| Price To Earning | 49.26 X | |||
| Price To Book | 8.15 X | |||
| Price To Sales | 5.55 X | |||
| Revenue | 1.65 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CochLear Pink Sheet Analysis
When running CochLear's price analysis, check to measure CochLear's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CochLear is operating at the current time. Most of CochLear's value examination focuses on studying past and present price action to predict the probability of CochLear's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CochLear's price. Additionally, you may evaluate how the addition of CochLear to your portfolios can decrease your overall portfolio volatility.